ICS/LABA safe and cut exacerbations: FDA explains why ‘black box’ removed
By Michael Woodhead
28 Jun 2018
Members of an FDA safety committee have explained why they took the unusual step of removing ‘black box’ safety warnings from combined inhaled corticosteroid-long acting beta agonist inhalers in December 2017. The warnings were originally put in place in 2011 as a precautionary measure after some trials involving LABA-containing inhalers suggested an increased risk of ...